Results 31 to 40 of about 683 (135)

Heart failure epidemiology and treatment in primary care: a retrospective cross‐sectional study

ESC Heart Failure, Volume 8, Issue 1, Page 489-497, February 2021., 2021
Abstract Aims Heart failure is one of the leading causes of morbidity and mortality worldwide, but little is known on heart failure epidemiology and treatment in primary care. This study described patients with heart failure treated by general practitioners, with focus on drug prescriptions and especially on the only specific treatment for heart ...
Yael Rachamin, Rahel Meier, Thomas Rosemann, Andreas J. Flammer, Corinne Chmiel   +4 more
wiley   +1 more source

Development and validation of RP-HPLC method for the simultaneous determination of azilsartan medoxomil and chlorthalidone in solid dosage form

Pakistan Journal of Pharmaceutical Sciences, 2023
The fixed dose combination of azilsartan medoxomil and chlorthalidone has been effectively used to treat hypertension. Development of a specific and accurate Reverse-Phase HPLC method for simultaneous estimation of AZL and CLR was main objective of this ...
Muhammad Jahangir, Arooj Azhar, Aymen Awan   +2 more
doaj   +1 more source

EFFICACY OF AZILSARTAN MEDOXOMIL ON THE DAILY PROFILE OF PERIPHERAL AND CENTRAL ARTERIAL PRESSURE AND ARTERIAL STIFFNESS IN HYPERTENSIVES WITH TYPE 2 DIABETES

Кардиоваскулярная терапия и профилактика, 2017
Comorbidity of diabetes  mellitus (DM) with arterial hypertension  (AH) leads to four-time increase of cardiovascular risk (CVR). Achievement of target blood pressure (BP) is one of the main strategies of cardiovascular complications  prevention in DM ...
E. A. Troitskaya, E. S. Starostina, Zh. D. Kobalava   +2 more
doaj   +1 more source

Azilsartan medoxomil: opportunities and prospects in diabetes mellitus

"Arterial’naya Gipertenziya" ("Arterial Hypertension"), 2021
Current data on the prevalence of hypertension and diabetes mellitus (DM) are presented. Concomitant DM complicates the course of cardiac diseases, affecting the effectiveness of antihypertensive therapy. Along with high blood pressure, lipid and carbohydrate metabolism parameters should be corrected.
A. M. Kochergina, O. L. Barbarash
openaire   +1 more source

Azilsartan Medoxomil, an Angiotensin II Receptor Antagonist for the Treatment of Hypertension [PDF]

Basic & Clinical Pharmacology & Toxicology, 2017
AbstractAzilsartan (AZL) medoxomil was approved by the United States Food and Drug Administration in 2011 for the treatment of hypertension and has shown promising results both in blood pressure (BP) reduction and in tolerability, but has not yet been taken into practice to the same extent as other angiotensin II receptor blockers (ARBs) that have been
Marie, Hjermitslev, Daniela G, Grimm, Markus, Wehland, Ulf, Simonsen, Marcus, Krüger   +4 more
openaire   +3 more sources

A Validated RP‐HPLC Stability Method for the Estimation of Chlorthalidone and Its Process‐Related Impurities in an API and Tablet Formulation

International Journal of Analytical Chemistry, Volume 2020, Issue 1, 2020., 2020
Low‐dose thiazide and thiazide‐like diuretics are widely used as first‐line therapy for hypertension. Chlorthalidone, a monosulfamyl diuretic, is frequently prescribed in cases of hypertension and congestive heart failure. In this research paper, an improved reverse‐phase HPLC method was developed for the simultaneous identification and quantitation of
Chaitali Kharat, Vaishali A. Shirsat, Yogita M. Kodgule, Mandar Kodgule, Valentina Venuti   +4 more
wiley   +1 more source

Azilsartan medoxomil for improving insulin resistance and adipokine levels in hypertension in comparison with angiotensin-converting enzyme inhibitors

Российский кардиологический журнал, 2020
Aim. To assess azilsartan medoxomil (AZM) in achieving the target blood pressure (BP) (<140/90 mm Hg), its angioprotective action in patients with hypertension (HTN), as well as contribution in reducing levels of adipokines and inflammation markers in
S. V. Nedogoda, E. V. Chumachek, V. V. Tsoma, T. N. Sanina, A. S. Salasyuk, V. O. Smirnova, E. A. Popova   +6 more
doaj   +1 more source

Efficacy of azilsartan medoxomil in patients with hypertension and stable coronary artery disease in combination with type 2 diabetes

Рациональная фармакотерапия в кардиологии, 2023
Aim. To study the effect of azilsartan medoxomil (AZL-M) on the 24-hour blood pressure (BP) profile in patients with hypertension (HTN), type 2 diabetes (T2D) and stable coronary artery disease (CAD).Material and methods.
A. M. Kochergina, O. L. Barbarash
doaj   +1 more source

Synthesis and characterization of related substances of Azilsartan Kamedoxomil

Current Issues in Pharmacy and Medical Sciences, 2017
Azilsartan Kamedoxomil is an AT1-subtype angiotensin II receptor blocker (ARB). During the laboratory synthesis of Azilsartan Kamedoxomil, four related substances of Azilsartan Kamedoxomil were observed and identified.
Maddi N. V. D. Harikiran, Garaga Srinivas, Reddy Ambati V. Raghava, Sanasi Paul Douglas, Korupolu Raghubabu   +4 more
doaj   +1 more source

Comparative Efficacy of Single Pill Combinations of Azilsartan Medoxomil/Chlorthalidone and Losartan/Hydrochlorothiazide in Patients with Hypertension and Heart Failure with Preserved Ejection Fraction

Рациональная фармакотерапия в кардиологии, 2022
Aim. To study the effects of azilsartan medoxomil/chlorthalidone (AZM/CTD) and losartan/hydrochlorothiazide (LOS/HCT) combinations for NTproBNP levels, 6-minute walk test results, hydration status along with their antihypertensive efficacy according to ...
Zh. D. Kobalava, A. F. Safarova, Kh. M. Gudieva, M. A. Markova, A. E. Petrosyan   +4 more
doaj   +1 more source